psoriasis
Conditions
Interventions
Control group:Secukinumab injection
Experimental Group:Secukinumab injection combined with oral administration of Huashixiaoyin prescription
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: A. Male or female aged 18 = = 75 years; B. Diagnosed with plaque psoriasis for = 6 months with or without psoriatic arthritis C. PGA = 3 PASI = 12 BSA = 10% at screening and baseline; D. Subjects who are intolerant to systemic treatment and/or phototherapy have contraindications or have poor treatment control and who are judged by the investigator to need systemic treatment. E. Subjects who meet the symptoms of psoriasis with spleen deficiency and dampness: According to the "Guidelines for Evidence-Based Clinical Practice of Traditional Chinese Medicine for Psoriasis Vulgaris (White Psoriasis) (2013 Edition)" and "Terms of Clinical Diagnosis and Treatment of Traditional Chinese Medicine·Syndrome Part".
Exclusion criteria
Exclusion criteria: A. History of psoriasis-related medication: history of topical medication in the previous 2 weeks history of traditional Chinese medicine medication in the previous month history of non-biological systemic medication or phototherapy; history of biological medication in the previous 3 months; history of Natalizumab Efalizumab or B cell or T cell regulator medication in the previous 12 months; B. BCG vaccination in the 12 months before treatment or live vaccine or bacterial vaccination in the 3 months; C. History of other systemic diseases; D. History of infection: history of infection with hepatitis B tuberculosis HIV etc.; history of chronic opportunistic and severe infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to relapse of patients during follow-up period from week 24 to week 48; | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of TCM symptom improvement at week 24 and week 48;Percentage of patients with PASI 75 at week 24;Percentage of patients with PASI 50 and PASI 90 at week 24;Percentage of patients with relapse during the follow-up period from week 24 to week 48; | — |
Countries
China
Contacts
Public ContactBai Yanping
China-Japan Friendship Hospital
Outcome results
None listed